Background: Cerebrospinal fluid (CSF) is in contact with brain parenchyma and ventricles, and its composition might influence the cellular physiology of oligodendrocyte progenitor cells (OPCs) thereby contributing to multiple sclerosis (MS) disease pathogenesis. Objective: To identify the transcriptional changes that distinguish the transcriptional response induced in proliferating rat OPCs upon exposure to CSF from primary progressive multiple sclerosis (PPMS) or relapsing remitting multiple sclerosis (RRMS) patients and other neurological controls. Methods: We performed gene microarray analysis of OPCs exposed to CSF from neurological controls, or definitive RRMS or PPMS disease course. Results were confirmed by quantitative reverse transcriptase polymerase chain reaction, immunocytochemistry and western blot of cultured cells, and validated in human brain specimens. Results: We identified common and unique oligodendrocyte genes for each treatment group. Exposure to CSF from PPMS uniquely induced branching of cultured progenitors and related transcriptional changes, including upregulation (P<0.05) of the adhesion molecule GALECTIN-3/Lgals3, which was also detected at the protein level in brain specimens from PPMS patients. This pattern of gene expression was distinct from the transcriptional programme of oligodendrocyte differentiation during development. Conclusions: Despite evidence of morphological differentiation induced by exposure to CSF of PPMS patients, the overall transcriptional response elicited in cultured OPCs was consistent with the activation of an aberrant transcriptional programme.
Introduction
Multiple sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system (CNS), characterized by demyelination, axonal damage and inefficient remyelination. 1, 2 Strategies to repair CNS myelin during the disease course of MS have gained significant momentum and many studies have focused on mechanisms responsible for impaired remyelination. 3, 4 In addition to intrinsic factors, progenitors are exposed to disease-specific changes in the environmental milieu possibly affecting their differentiation and the ability to repair damaged myelin. CSF is in contact with the brain parenchyma 5, 6 and might influence the cellular physiology of oligodendrocyte progenitor cells (OPCs). Extensive studies have been performed in order to identify soluble factors that mediate nervous system damage and inhibit repair in distinct types of MS, including proteomics, 7-9 metabolomics, 10, 11 RNA expression in peripheral blood 12 and microRNAs. [13] [14] [15] Numerous studies have attempted to identify soluble factors in the CSF of MS patients that could account for the observed cellular effects. For example, we recently showed that ceramides present in MS CSF promote axonal injury and neuronal damage through oxidative stress mechanisms and mitochondrial bioenergetic failure. 16 In addition, microarray profiling of MS cortical gray matter revealed gene changes in oxidative stress and remyelination/repair pathways. 17 This study was designed to define the transcriptional changes occurring in proliferating OPCs, after exposure to the CSF of patients with a distinct disease course. We found that proliferating OPCs exposed to CSF from primary progressive multiple sclerosis (PPMS) patients upregulate the expression of molecules implicated in OPC morphological differentiation, while downregulating genes, which are highly expressed during developmental myelination. We conclude that the CSF from PPMS patients induces an aberrant transcriptional response in rat OPCs.
Materials and methods
Subject material CSF was collected by lumbar puncture from MS patients. We selected patients with definitive MS from our database according to the 2010 McDonald criteria. For our study we selected two clinical forms of MS: a set of PPMS patients, defined by a progressive onset for more than one year of neurological dysfunction with magnetic resonance Swanton criteria of dissemination in space (McDonald criteria), and in which IgG oligoclonal bands were present in both the serum and the CSF, with more bands presents only in the CSF, an oligoclonal band pattern that has been recognized as more specific of PPMS. The second form consisted of a relapsing remitting multiple sclerosis (RRMS) patient cohort defined by two or more relapses separated by one month, Swanton criteria for dissemination in time and space, and the presence of oligoclonal band of the IgG type in the CSF. 16, 17 The control cohort consisted of patients with other neurological disorders including parainfectious myelitis, Miller-Fisher syndrome and amyotrophic lateral sclerosis. The spinal fluid was immediately placed on ice, aliquoted and snap frozen on dry ice. Post-mortem human brain samples from the frontal lobe region were obtained from the UK Multiple Sclerosis Tissue Bank and UCLA Brain Bank.
Oligodendrocyte cultures
OPCs were isolated from the cortex of postnatal day 1 rats and cultured according to the published procedure 18 in oligodendrocyte chemically defined media (ODM). Cells were allowed to proliferate for 48 hours in chemically defined media supplemented with growth factors (GFs) (20 ng/mL basic fibroblast growth factor and 10 ng/mL platelet-derived growth factor AA prior to treatment.
CSF treatment, RNA extraction and quantitative polymerase chain reaction
OPCs were treated with a 1:1 dilution of CSF in ODM with GFs for 24 hours and RNA was extracted following the Qiagen RNeasy kit manufacturer's instructions, and concentrations were determined using NanoDrop and quality verified by using the 2100 Bioanalyzer instrument (Agilent Technologies, Santa Clara, CA). For RNA extraction from human brain, normal-appearing white matter (NAWM) was dissected from surrounding tissue and RNA isolated using TRIzol (Invitrogen, Grand Island, NY) and subsequent purification with RNeasy columns (Qiagen, Valencia, CA). Complementaryh DNA was synthesized from 1 μg of total RNA, using Quanta Biosciences qScript cDNA SuperMix kit, according to the manufacturer's instructions, and amplified using gene-specific primers (Table 1) , and normalization to Gapdh (rat) or GAPDH, DHX32 and RPLP0 (human).
MTT assay
The MTT assay was performed as previously described. 19 After 24 hours of treatment, 5 mg/mL MTT was added to the cell media to a final concentration of 0.05 mg/mL and allowed to incubate for 4 hours to allow MTT reduction. The formazan precipitate formed by viable cells was solubilized in dimethyl sulphoxide and read spectrophotometrically at 540 nm with background subtraction at 655 nm.
Gene microarray, data normalization and gene validation
The labeled cRNA was hybridized to Agilent SurePrint G3 Rat GE8x60K Microarray (GEO-GPL13521, in situ oligonucleotide) according to the manufacturer's protocol. Briefly, the messenger RNA was reverse transcribed in the presence of T7-oligo-dT primer, labeled and scanned on an Agilent G2565CA microarray scanner. Data were extracted using the feature extraction software (Agilent). Statistical analysis was conducted after background noise correction using the NormExp method. 20 Differential expression analysis was carried out on non-control probes with an empirical Bayes approach on linear models. 31 Results were corrected for multiple testing hypothesis using the false discovery rate (FDR), and all statistical analyses were performed using the Bioconductor project (http://www.bioconductor. org/) in the R statistical environment (http://cran.r-project. org/). 21 To filter out low expressed features, the 30% quantile of the whole array was calculated, and probe sets falling below threshold were filtered out. After merging the probes corresponding to the same gene on the microarray, the statistical significance of difference in gene expression was assessed using a standard oneway analysis of variance (ANOVA) followed by Tukey's HSD post hoc analysis (cut-off P<0.01 and FDR <0.1). All data processing and analysis including principal component analysis plot was carried out using R functions.
Immunostaining
Immunocytochemistry of OPCs was performed as previously described. 22 Briefly, cells were fixed and incubated overnight in anti-GALECTIN-3 antibody (1:100, sc-20157, Santa Cruz Biotechnology Inc., Dallas, TX) diluted in blocking solution (10% goat serum in PGBA) (0.1 M Phosphate Buffer, 0.1% gelatin, 1% Bovine Serum Albumin, 0.002% azide) followed by detection using fluorophore-conjugated secondary antibodies. For histological analysis frozen blocks of human brain were sectioned and slides were post-fixed in ice-cold methanol, quenched by incubation in hydrogen peroxide followed by antigen retrieval in citric acid buffer (pH 6.0) and incubation with mouse anti-GALECTIN-3 primary antibody (1:50, ab2787; Abcam, Cambridge, MA) followed by biotinylated secondary antibodies (Mount Sinai Shared Resource Facility).
Western blotting
Western blotting was performed as previously described. 18 Briefly, proliferating oligodendrocyte progenitors were plated in 6-well poly-d-lysine coated plates, and treated with 1 mL of a 1:1 mixture of CSF: serum-free medium plus GFs for 24 hours. Cells were harvested in RIPA lysis buffer containing protease (Roche, Nutley, NJ) and phosphatase inhibitors (Sigma, St. Louis, MO). Ten micrograms of protein lysates were electrophoresed and blots were probed with antibodies for GALECTIN-3 (1:200, Santa Cruz, sc-20157) and actin (1:1000, clone AC-40; Sigma). Blots were visualized using the Enhanced ECL detection system (Amersham, Pittsburgh, PA). Quantification was performed using ImageJ. 
Data analysis and overlap
Uniquely upregulated or downregulated genes in OPC by exposure to PPMS CSF were compared with a known oligodendrocyte-specific transcriptome database. 23 We overlaid the uniquely up or downregulated genes in PPMS versus control with the entire RNA-seq database in 'oligodendrocyte precursor cell', 'newly formed oligodendrocyte' and 'myelinating oligodendrocytes'.
Results
As progenitor cells in the human brain have the ability to come into close contact with the CSF, we hypothesized that understanding how exposure to human CSF from RRMS or PPMS patients might affect gene expression, may uncover a disease subtype-specific transcriptional difference in oligodendrocyte lineage cells and inform us of potential differences in pathobiology. The purpose of our study was to determine the effect of exposure to CSF from patients with either PPMS or RRMS on the transcriptional signatures of cultured OPCs. CSF samples from neurological patients (including an amyotrophic lateral sclerosis patient with numerous T2-weighted lesions corresponding to concurrent ischemic strokes) were used as controls (Figure 1(a) ). Of note is that controls and PPMS patients were characterized by similar disability. Proliferating rat OPCs were exposed for 24 hours to CSF diluted 1:1 in chemically defined media ( Figure  1(b) ) and the effect on viability (Figure 1(c) ), morphology ( Figure 2 ) and transcripts (Figures 2 and 3 ) changes were evaluated. We first performed an MTT cellular toxicity assay to determine whether CSFexposed OPCs were viable (Figure 1(c) ) and no difference was detected among the CSF groups tested (P>0.05).
Patient-derived CSF induces unique morphological and transcriptional changes in proliferating OPCs
A striking observation was the detection of a more highly branched phenotype only in OPCs exposed to the CSF from PPMS patients (Figure 2(a) ). Quantification of the number of primary branches revealed a statistically significant (P<0.001) increase only in cells treated with the CSF from PPMS patients, but not with the CSF from RRMS patients or from controls with other neurological diseases (Figure 2(b) ). These morphological changes were also associated with an overall pattern suggestive of a pro-differentiative effect, including downregulation of transcript levels for Lingo1 and Pdgfra and concomitant upregulation of the myelin gene Mag (Figure 2(c) ). Together these changes were suggestive of a pro-differentiative effect of the CSF from PPMS patients on OPCs.
We next performed an Agilent microarray analysis to determine whether the changes that occurred in proliferating OPCs in response to patient CSF were consistent with a global reorganization of the transcriptional signature of oligodendrocyte differentiation. We performed gene expression value normalizations, and filtered out low expressed transcripts, followed by ANOVA with Tukey's multiple comparison test (Figure 3 (a)) in order to determine genes that were significantly changed compared to control samples. A principal component analysis revealed the transcripts in treated OPCs clustered according to patient diagnosis, with the CSF from RRMS patients inducing the most dramatic changes (Figure 3(b) ). The overlap of genes that were differentially regulated in OPCs after treatment for 24 hours with the CSF from PPMS or RRMS (Figure 3(c) ), revealed 29.6% of upregulated genes and 32.1% of downregulated genes in common between the two treatment groups (Figure 3(d) ). The RRMS specimens in general induced a much more robust transcriptional response compared to the PPMS. Gene ontology (GO) analysis of the genes upregulated by exposure to the CSF of either RRMS or PPMS revealed genes involved in protein transport, actin filament-based processes, protein complex disassembly and nucleocytoplasmic transport (Figure 3(e) ). Downregulated GO categories included response to DNA damage stimulus, protein modification by small protein conjugation or removal, mitochondrial organization and oxidative phosphorylation (Figure 3(f) ). Together these data revealed transcriptional changes that were induced in OPCs by exposure to the CSF of MS patients, regardless of the disease type, but not by the CSF of patients with other neurological diseases. Of the genes similarly regulated by exposure to the CSF from the RRMS or PPMS group, we noted Pcyt1a, a gene involved in lipid metabolism 19 and Rnf26, a gene encoding for a transcriptional regulator 20 (Figure 4(a) ). Transcripts uniquely induced by the CSF from RRMS included Ppt1 encoding for a protein involved in lipid catabolism 21 and Pla2g7 a gene encoding for the phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma), which uses phosphatidylcholine as substrate to generate lysophosphatidylcholine and arachidonic acid 22 (Figure 4(b) ). Together these results suggested important differences induced in OPCs by treatment with CSF from PPMS or RRMS patients.
Aberrant transcriptional changes in cultured OPCs exposed to the CSF from patients with a diagnosis of PPMS or RRMS
In an attempt to determine whether the CSF from PPMS patients induced a pro-differentiative response we overlapped our dataset with recently published RNA sequencing data ( Figure 5(a) ) in cultured oligodendrocyte progenitors differentiated into oligodendrocytes. 23 We noted further that the percentage of overlap between transcripts decreased by CSF exposure and developmentally regulated genes was 60% ( Figure 5(b) ), and included genes previously shown to be downregulated during oligodendrocyte development including Brevican (Bcan), which has been implicated inregulating process outgrowth in differentiating oligodendrocyte progenitors, 24 Stk 38 and Stk10, which encode for serine-threonine kinases with the ability to inhibit mitogen-activated protein kinase activity in cells 25, 26 ( Figure 5(c) ). Remarkably, the exposure to the CSF from PPMS patients, but not from RRMS induced a downregulation similar to that detected during the normal process of differentiation ( Figure 5(c) ). Despite these concordant changes, we also detected changes that were discordant between the CSF induction and the physiological process of differentiation. One example was the expression of Bcat1 and Pik3r3, which were downregulated in OPCs exposed to the CSF and upregulated during differentiation ( Figure 5(d) ). Of the genes that were upregulated by PPMS treatment, we noticed that over 90% were also present in the oligodendrocyte transcriptome ( Figure 5(e) ). However, also in this case the changes were discordant, as transcripts that were downregulated in differentiating oligodendrocytes during developmental myelination were upregulated by exposure to the CSF from PPMS patients (Figure 6(a) ).
Particularly relevant was the gene Lgals3, which encodes GALECTIN-3 and was only upregulated in the PPMS group. This gene had previously been implicated in diverse cellular functions, including cell adhesion and growth and also OPC branching. 27 To understand further whether this increase was also reflected in higher protein levels, we performed immunocytochemistry with GALECTIN-3 antibodies in primary cultures of proliferating OPCs exposed to the CSF from control subjects or from patients with a diagnosis of RRMS or PPMS ( Figure 6(b) ). Consistent with a protein upregulation, GALECTIN-3 signal intensity was increased 1.4 fold (P<0.01) in oligodendrocyte lineage cells exposed to PPMS CSF compared to RRMS or control ( Figure 6 (c)) and this corresponded to a twofold increase in the number of primary branches extending from the soma (P<0.001). Western blot analysis confirmed the upregulation of GALECTIN-3 in cultured cells (Figure 6(d) and (e)). Exposure to the CSF from PPMS thus triggered an aberrant transcriptional response characterized by the upregulation of genes involved in morphological differentiation.
LGALS3 mRNA transcript levels are upregulated in human post-mortem PPMS brain NAWM To validate the findings in rodent OPCs in humans, we also analyzed RNA that was isolated from postmortem brain tissue from patients with a secondary progressive or primary progressive disease course at the time of death (Table 3) . We opted to measure the transcripts only in the NAWM of human patients; in order to avoid potential complications consequent to cellular infiltration, we only selected tissue devoid of inflammatory cells, as also previously described. 28 Interestingly, we detected an increasing trend for LGALS3 levels in secondary progressive multiple sclerosis (SPMS) patients, with even higher levels in patients with a primary progressive disease course (Figure 7(a) ). Also in this case the increased transcript levels were accompanied by the detection of higher protein levels in MS brain sections (Figure 7(b) ).
Discussion
This study was designed to determine whether human CSF samples from patients with a benign or aggressive disease course could differentially modulate the behavior of cultured OPCs. In MS lesions, OPCs migrate to plaque areas, but often fail to remyelinate efficiently possibly due to aberrant intracellular signaling pathways, and extracellular factors inhibiting differentiation (for review see Lau et al, 2013) 29 and inefficient repair could result in a more aggressive disease course. In this study we tested the overarching hypothesis that soluble factors in the CSF could influence the ability of OPCs to differentiate and therefore affect their ability to repair damaged myelin effectively. Because OPC differentiation is characterized by the execution of a complex transcriptional programme, we sought to determine the unique transcriptional signature induced in cultured OPCs by exposure to the CSF from MS patients with a more benign (i.e. RRMS) or aggressive (i.e. PPMS) disease course. One of the most striking observations was that exposure to CSF from the RRMS group resulted in large changes of the OPC transcriptome, while only a small number of unique transcriptional changes occurred in OPCs exposed to CSF from PPMS patients. These results are consistent with the fact that the PPMS disease course is characterized by prominent neurodegeneration, and modest inflammatory demyelination and possibly fewer soluble ligands in the CSF.
A recent paper had reported that the CSF from patients with a diagnosis of PPMS and SPMS could induce differentiation of human neural precursor cells in vitro. 30 However, only specific markers were tested to evaluate differentiation. Our study employs an array method to evaluate the overall effect of the exposure to CSF from PPMS or RRMS patients on the OPC transcriptome. In agreement with the previously published study, we noticed that only the CSF from PPMS patients (and not from RRMS) elicited a pro-differentiative response in OPCs, that was defined in terms of increased branching, as a sign of morphological differentiation, downregulation of molecules associated with the progenitor state (i.e. Lingo1, Pdgfra,) and a modest upregulation of the myelin gene Mag. The increased branching was correlated with the detection of higher transcript levels of Lgals3, a gene encoding for the galactosidebinding protein GALECTIN-3, that has previously been involved in promoting OPC branching. 27 The exact mechanism as to how GALECTIN-3 regulates OPC differentiation is unknown; however, carbohydrate interactions may mediate its effect. Interestingly in physiological conditions Lgals3 is mostly expressed by astrocytes and microglia and downregulated during the process of OPC differentiation. In OPCs exposed to PPMS CSF, however, GALECTIN-3 is upregulated and this results in enhanced branching. These transcriptional changes occurred not only in rodent cells but were also detected in human NAWM from both SPMS and PPMS patients, and it was associated with a corresponding increase in protein levels. Unfortunately, however, despite the evidence of pro-differentiative effects of the exposure to CSF from PPMS patients, the overall transcriptional changes induced by the CSF were discordant with those occurring during the differentiation of OPC into oligodendrocytes, and this revealed the activation of an aberrant transcriptional programme in OPCs, which was likely to be associated with impaired differentiation. This suggests that molecules in the CSF of PPMS patients have the capability to upregulate genes associated with a pro-differentiative effect but are unable to induce the entire transcriptional programme leading to successful differentiation and enhanced repair. Future studies are needed to determine the identity of these signals and the precise intracellular mechanism modulating the transcriptional effects. N3543  F  73  --12  COPD  CO14  M  64  --18  MI, TIA   PDC05  M  58  --NA  Cervical ependymoma  CO51  M  68  --24  IHD  N3276  M  54  --19 CHD, CKD, PVD 
